Kunchok A, Aksamit Jr AJ, Davis III JM, Kantarci OH, Keegan M, Pittock SJ, Weinshenker BG, McKeon A. Association between tumor necrosis factor inhibitor exposure and inflammatory central nervous system events. JAMA Neurology 2020:18 de mayo. [Ref.ID 103656]

Esse S, Mason KJ, Green AC, Warren RB. Melanoma risk in patients treated with biologic therapy for common inflammatory diseases. A systematic review and meta-analysis. JAMA Dermatol 2020:20 de mayo. [Ref.ID 103629]

Taylor P. BMS completes Celgene merger after FTC okay. PMLiVE 2019:18 de noviembre. [Ref.ID 103210]

Dommasch ED, Kim SC, Lee MP, Gagne JJ. Risk of serious infection in patients receiving systemic medications for the treatment of psoriasis. JAMA Dermatol 2019:10 de mayo. [Ref.ID 103131]

Lyman GH, Zon R, Harvey RD, Schilsky RL. Rationale, opportunities, and reality of biosimilar medications. N Engl J Med 2018;378:24 de mayo. [Ref.ID 102636]

Anónimo. Baricitinib et polyarthrite rhumatoïde. Prescrire 2018;38:171-2. [Ref.ID 102586]

Anónimo. Arthritis drug prices rise 70 percent in three years despite increased competition. DIA Daily 0:1. [Ref.ID 102183]

Pinto RZ, Verwoerd AJH, Koes BW. Which pain medications are effective for sciatica (radicular leg pain)?. BMJ 2017;359:j4248. [Ref.ID 102095]

Greenway T, Ross JS. US drug marketing: how does promotion correspond with health value?. BMJ 2017;357:j1855. [Ref.ID 101571]

Alijotas-Reig J, Esteve-Valverde E. Embarazo y enfermedades autoinmunitarias. Med Clin (Barc) 2017;148:161-3. [Ref.ID 101400]

Anónimo. Encéphalopathies postérieures réversibles d'origine médicamenteuse. Prescrire 2016;36:907-10. [Ref.ID 101007]

Smolen JS, Aletaha D, McInnes IB. Rheumatoid arthritis. Lancet 2016;388:2023-38. [Ref.ID 100911]

Anónimo. Ustékinumab et psoriasis chez les adolescents. Prescrire 2016;36:733-4. [Ref.ID 100889]

Anónimo. Sécukinumab et rumatisme psoriasique. Prescrire 2016;36:732. [Ref.ID 100888]

Anónimo. Sécukinumab et psoriasis en plaques. Prescrire 2016;36:727-31. [Ref.ID 100887]

Gottenberg J-E, Brocq O, Perdriger A, Lassoued S, Berthelot J-M, Wendiing D, Euller-Ziegler L, Soubrier M, Richez C, Fautrel B, Constantin AL, Mariette X, Morel J, Gilson M, Cormier G, Salmon JH, Rist S, Lioté F, Marotte H, Bonnet C, Marcelli C, Sellam J, Meyer O, Solau-Gervais E, Guis S, Ziza J-M, Zarnitsky C, Chary-Valckenaere I, Vittecoq O, Saraux A, Pers Y-M, Gayraud M, Bolla G, Glaudepierre P, Ardizzone M, Dernis E, Breban MA, Fain O, Balblanc J-C, Aberkane O, Vazel M, Back C, Candon S, Chatenoud L, Perrodeau E, Sibilia J, Ravaud P. Non-TNF-tarteged biologic vs a second anti-TNF drug to treat rheumatoid arthritis in patients with insufficient response to a first anti-TNF drug: a randomized clinical trial. JAMA 2016;316:1172-80. [Ref.ID 100753]

Porter D, van Melckebeke J, Dale J, Messow CM, McConnachie A, Walker A, Munro R, McLaren J, McRorie E, Packham J, Buckley CD, Harvie J, Taylor P, Choy E, Pitzalis C, McInnes IB. Tumour necrosis factor inhibition versus rituximab for patients with rheumatoid arthritis who require biological treatment (ORBIT): an open-label, randomised controlled, non-inferiority, trial. Lancet 2016;388:239-47. [Ref.ID 100631]

Anónimo. FDA approves biosimilar version of etanercept. DIA Daily 2016:1. [Ref.ID 100615]

Anónimo. Aprémilast. Prescrire 2016;35:90-4. [Ref.ID 100523]

Anónimo. Drugmakers using new patents to delay introduction of biosimilars. DIA Daily 2016:6. [Ref.ID 100496]